PubMed:36519389 JSONTXT

{"project":"Linmchun_800_3","denotations":[{"id":"T1","span":{"begin":242,"end":263},"obj":"CI"},{"id":"T10","span":{"begin":154,"end":157},"obj":"CI"},{"id":"T11","span":{"begin":163,"end":166},"obj":"CI"},{"id":"T12","span":{"begin":167,"end":170},"obj":"CI"},{"id":"T13","span":{"begin":171,"end":180},"obj":"CI"},{"id":"T14","span":{"begin":184,"end":187},"obj":"CI"},{"id":"T15","span":{"begin":188,"end":198},"obj":"CI"},{"id":"T16","span":{"begin":199,"end":202},"obj":"CI"},{"id":"T17","span":{"begin":265,"end":268},"obj":"CI"},{"id":"T18","span":{"begin":270,"end":283},"obj":"CI"},{"id":"T19","span":{"begin":285,"end":288},"obj":"CI"},{"id":"T2","span":{"begin":50,"end":71},"obj":"CI"},{"id":"T20","span":{"begin":290,"end":302},"obj":"CI"},{"id":"T21","span":{"begin":304,"end":307},"obj":"CI"},{"id":"T22","span":{"begin":310,"end":339},"obj":"CI"},{"id":"T23","span":{"begin":341,"end":344},"obj":"CI"},{"id":"T24","span":{"begin":346,"end":349},"obj":"CI"},{"id":"T25","span":{"begin":352,"end":355},"obj":"CI"},{"id":"T26","span":{"begin":360,"end":363},"obj":"CI"},{"id":"T27","span":{"begin":364,"end":367},"obj":"CI"},{"id":"T28","span":{"begin":368,"end":377},"obj":"CI"},{"id":"T29","span":{"begin":379,"end":382},"obj":"CI"},{"id":"T3","span":{"begin":72,"end":85},"obj":"CI"},{"id":"T30","span":{"begin":420,"end":423},"obj":"CI"},{"id":"T31","span":{"begin":424,"end":434},"obj":"CI"},{"id":"T32","span":{"begin":441,"end":444},"obj":"CI"},{"id":"T33","span":{"begin":489,"end":492},"obj":"CI"},{"id":"T34","span":{"begin":493,"end":496},"obj":"CI"},{"id":"T35","span":{"begin":499,"end":502},"obj":"CI"},{"id":"T36","span":{"begin":506,"end":509},"obj":"CI"},{"id":"T37","span":{"begin":510,"end":513},"obj":"CI"},{"id":"T38","span":{"begin":514,"end":517},"obj":"CI"},{"id":"T39","span":{"begin":521,"end":524},"obj":"CI"},{"id":"T4","span":{"begin":87,"end":90},"obj":"CI"},{"id":"T40","span":{"begin":529,"end":532},"obj":"CI"},{"id":"T5","span":{"begin":92,"end":104},"obj":"CI"},{"id":"T6","span":{"begin":106,"end":109},"obj":"CI"},{"id":"T7","span":{"begin":112,"end":141},"obj":"CI"},{"id":"T8","span":{"begin":143,"end":146},"obj":"CI"},{"id":"T9","span":{"begin":148,"end":151},"obj":"CI"},{"id":"T41","span":{"begin":525,"end":528},"obj":"CI"},{"id":"T42","span":{"begin":436,"end":439},"obj":"CI"}],"text":"Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.\nParticipants randomized to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks. Participants switching either TAF/FTC + DTG or TDF/FTC/EFV to TDF/3TC/DTG showed statistically significant reductions in weight, low-density lipoprotein, triglycerides, glucose and glycated hemoglobin."}

{"project":"luoyt2021_800_3","denotations":[{"id":"T1","span":{"begin":50,"end":71},"obj":"CI"},{"id":"T10","span":{"begin":364,"end":367},"obj":"CI"},{"id":"T11","span":{"begin":346,"end":349},"obj":"CI"},{"id":"T12","span":{"begin":285,"end":288},"obj":"CI"},{"id":"T13","span":{"begin":167,"end":170},"obj":"CI"},{"id":"T14","span":{"begin":148,"end":151},"obj":"CI"},{"id":"T15","span":{"begin":92,"end":104},"obj":"CI"},{"id":"T16","span":{"begin":106,"end":109},"obj":"CI"},{"id":"T17","span":{"begin":529,"end":532},"obj":"CI"},{"id":"T18","span":{"begin":441,"end":444},"obj":"CI"},{"id":"T19","span":{"begin":499,"end":502},"obj":"CI"},{"id":"T20","span":{"begin":352,"end":355},"obj":"CI"},{"id":"T21","span":{"begin":304,"end":307},"obj":"CI"},{"id":"T22","span":{"begin":199,"end":202},"obj":"CI"},{"id":"T23","span":{"begin":154,"end":157},"obj":"CI"},{"id":"T24","span":{"begin":143,"end":146},"obj":"CI"},{"id":"T25","span":{"begin":163,"end":166},"obj":"CI"},{"id":"T26","span":{"begin":184,"end":187},"obj":"CI"},{"id":"T27","span":{"begin":368,"end":377},"obj":"CI"},{"id":"T28","span":{"begin":379,"end":382},"obj":"CI"},{"id":"T29","span":{"begin":420,"end":423},"obj":"CI"},{"id":"T3","span":{"begin":242,"end":263},"obj":"CI"},{"id":"T30","span":{"begin":424,"end":434},"obj":"CI"},{"id":"T31","span":{"begin":310,"end":339},"obj":"CI"},{"id":"T32","span":{"begin":341,"end":344},"obj":"CI"},{"id":"T33","span":{"begin":506,"end":509},"obj":"CI"},{"id":"T34","span":{"begin":510,"end":513},"obj":"CI"},{"id":"T35","span":{"begin":514,"end":517},"obj":"CI"},{"id":"T36","span":{"begin":521,"end":524},"obj":"CI"},{"id":"T37","span":{"begin":525,"end":528},"obj":"CI"},{"id":"T38","span":{"begin":436,"end":439},"obj":"CI"},{"id":"T4","span":{"begin":265,"end":268},"obj":"CI"},{"id":"T5","span":{"begin":112,"end":141},"obj":"CI"},{"id":"T6","span":{"begin":489,"end":492},"obj":"CI"},{"id":"T7","span":{"begin":72,"end":85},"obj":"CI"},{"id":"T8","span":{"begin":87,"end":90},"obj":"CI"},{"id":"T9","span":{"begin":493,"end":496},"obj":"CI"},{"id":"T39","span":{"begin":360,"end":363},"obj":"CI"},{"id":"T40","span":{"begin":270,"end":283},"obj":"CI"},{"id":"T41","span":{"begin":188,"end":198},"obj":"CI"},{"id":"T42","span":{"begin":290,"end":302},"obj":"CI"},{"id":"T43","span":{"begin":171,"end":180},"obj":"CI"}],"text":"Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.\nParticipants randomized to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks. Participants switching either TAF/FTC + DTG or TDF/FTC/EFV to TDF/3TC/DTG showed statistically significant reductions in weight, low-density lipoprotein, triglycerides, glucose and glycated hemoglobin."}